Gilead Sciences Inc (GILD)

Currency in USD
125.19
+1.03(+0.83%)
Closed·
125.52+0.33(+0.26%)
·

Gilead (GILD) Earnings Dates & Reports

Latest Release
Oct 30, 2025
EPS / Forecast
2.47 / 2.15
Revenue / Forecast
7.80B / 7.45B
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2025--/1.86--/7.65B----Free Sign Up
09/20252.47/2.157.8B/7.45B+14.88%+4.7%Free Sign Up
06/20252.01/1.967.1B/6.97B+2.55%+1.87%Free Sign Up
03/20251.04/1.776.67B/6.78B-41.24%-1.62%Free Sign Up
12/20241.9/1.717.6B/7.16B+11.11%+6.15%Free Sign Up
09/20242.02/1.517.54B/7.01B+33.77%+7.56%Free Sign Up
06/20242.01/1.67B/6.72B+25.62%+4.17%Free Sign Up
03/2024-3.34/1.566.65B/6.36B-314.1%+4.56%Free Sign Up
12/20231.72/1.767.1B/7.1B-2.27%0%Free Sign Up
09/20232.29/1.917.1B/6.81B+19.9%+4.26%Free Sign Up

All numbers in USD

Gilead Sciences Inc Earnings Call Summary for Q3/2025

  • Gilead Sciences exceeded Q3 2025 expectations with EPS of $2.47 (14.88% above forecast) and revenue of $7.8 billion, driven by strong HIV and oncology sales growth
  • The company raised full-year product sales guidance to $27.4-$27.7 billion, projecting approximately 5% year-over-year growth for its HIV franchise
  • Key products Biktarvy and Descovy showed robust growth (6% and 20% respectively), while new HIV prevention product YES2GO contributed $39 million in sales
  • Despite strong performance, stock movement remained modest with a 0.05% decline at close ($118.50) but rising 0.41% in aftermarket trading
  • Management expressed confidence for 2026, citing upcoming product launches including Trodelvy and potential lenacapavir treatment, targeting 90% payer coverage for YES2GO
Last Updated: 10/30/2025, 07:00 PM
Read Full Transcript
Gilead investor slides for Q3/2025
Gilead Q3 2025 slides
Last Update: Oct 30, 2025
See full investor slides

FAQ

What Is Gilead's Earnings Per Share (TTM)?

The Gilead EPS (TTM) is 6.42.

When Is The Next Gilead Earnings Date?

Gilead will release its next earnings report on Feb 10, 2026.

What Is Gilead’s Revenue Forecasts For Upcoming Quarters?

Gilead’s revenue forecast is 7.65B.

How Did Gilead React to the Company's Latest Earnings Report?

Gilead reported a +14.88% EPS surprise and a +4.7% revenue surprise, comparing the latest report against analyst forecasts. The stock price changed by 1.09%, reflecting the market's response to the earnings results.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.